Abstract
The value of testing for Epstein-Barr virus status before starting immunosuppression in children with inflammatory bowel disease remains unproven.
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
This output has contributed to the advancement of the following goals:
Source: InCites